What the Tendon Research on BPC-157 Actually Measured

The story below is a composite of real experiences; details changed.

“BPC-157. Heals tendons. Look it up.”

That’s the text Wes Harlan’s cousin sends him one night, with a video attached. Wes reads it on the couch, his elbow still throbbing from a day of trim.

Wes is 46 and hangs cabinet trim for a living. For nine months, the outside of his right elbow has hurt every time he grips a hammer.

PT helped at first. Then it stalled. With a living that runs on grip, a text like that is hard to ignore.

So he looks it up. Every page says the same thing. Almost none of them say what was actually tested, or in what.

Here’s what the BPC-157 tendon studies actually tested, what they found, and where they stop short of an elbow like yours.

Why tendons are where the peptide talk starts

Researchers describe BPC-157 as a peptide found in gastric juice, where it helps protect the lining of the stomach.

Its reputation in sports medicine comes from the lab. A 2025 review in HSS Journal pulled together the orthopedic research. It reported:

• Better tendon structure, mechanics and function after rat Achilles and quadriceps tendons were cut.
• Better knee stability after a cut ligament, in one rat study.
• Better healing in three rat muscle-injury studies.

That’s a lot of positive animal work. It’s the reason researchers keep studying it.

What the classic rat studies measured

Sources: 2003 Achilles study; 2006 tendon-to-bone study; 2025 review.

A pull test clamps the tendon in a machine and measures the force it takes to tear it. It measures strength, not pain.

The 2026 study that tested BPC-157 against TB-500

This year, a new rat study put BPC-157 and TB-500 side by side. (Joint Diseases and Related Surgery, 2026)

• Setup: 32 rats had the Achilles cut and stitched back together. They were split into four groups: untreated, BPC-157, TB-500 and both.
• Measured at four weeks: breaking strength, tissue quality under the microscope and collagen.
• Strength: higher in both treated groups, but only TB-500 was statistically significant. BPC-157 alone was not (p = 0.389).
• Tissue: BPC-157’s scores looked better on paper, but not significantly.
• Both together: no better than either one alone.

“Not significant” means the difference could plausibly be chance. The authors call their own results “hypothesis-generating rather than confirmatory.”

A promising signal for TB-500 in one rat study. For BPC-157, a reason to repeat the work, not a verdict. For the bigger picture, see how TB-500 and BPC-157 compare.

A cut rat tendon isn’t a nine-month elbow

Every tendon study above began with a surgical cut in a healthy animal. None of them modeled months of overuse pain. None of them involved the elbow.

The 2026 authors flag this themselves. They note that using “healthy young male rats” may limit how well the results apply to real patients. And they warn that “direct extrapolation from healthy young rat models to human populations should be approached with caution.”

Then there’s time. The rats were followed for two to four weeks. Wes has hurt for nine months.

Long-standing tendon pain behaves differently from a fresh cut. For a closer look, read why the Achilles tendon is a different problem.

What’s been studied in people

• One small human study. Of the 36 studies in the 2025 review, one involved people: a look back at 12 patients with unspecified chronic knee pain. Seven said they felt better for more than six months. It wasn’t about tendons, and it had no comparison group.
• No human safety data. The review found “no clinical safety data.”
• Trials are starting. A randomized trial of BPC-157 in hamstring muscle strain is recruiting. It plans 120 people, with main data collection estimated to finish in February 2027. (NCT07437547) A small rotator cuff repair study was registered in September 2026. (NCT07803250) We found no registered trial in long-standing tendon pain.
• Not an approved drug. FDA’s 2026 review found no approved product containing BPC-157 in any country. (FDA)

Real interest, real animal data, and no human tendon data yet. For the full evidence ladder, read what the BPC-157 research actually shows.

The BPC-157 profile in the Peptides Made Simple peptide library (from the team behind After the Scope) sums up the animal and human research on one page.

Five questions for any tendon study

Ask the same questions about every treatment, including the ones already in your plan. If your rehab has stalled, start with what to reassess when PT stalls.

Three words on a sticky note

Wes runs his cousin’s video through the five questions. Then he writes three words on a sticky note: rat, fresh cut, four weeks. Under them he adds one more line: Ask my PT what the next phase is.

He texts his cousin back: “Watched it. Rats, not elbows. I’m asking my PT what’s next.”

He’s still curious about the research. Curious is fine. He just knows now what it can and can’t tell him.

Read the model before you read the headline.

Your next step: at your next PT visit, ask, “What’s the next phase for this elbow, and how will we know it’s working?”

---

Wes is a composite, drawn from the kinds of questions tradespeople ask about tendon pain. The details are illustrative. This article is education, not medical advice. Research compounds are sold for laboratory research only, and nothing here is a recommendation to use any compound.